Pfizer's recent financial performance shows 14% YoY operational growth excluding COVID sales. Check out more on PFE stock ...

Phase I data for TERN-601 suggests Terns’ oral GLP-1 candidate for obesity could be a contender in the market next to big ...

The race is on to develop the first daily weight-loss pill that would be both cheaper and less invasive than the current ...

Terns Pharmaceuticals will advance TERN-601 into Phase II after early-stage data showed the oral therapy led to weight loss ...

The market for obesity treatment is expected to expand more than fifteenfold by 2030 due to escalating competition, fueled by ...

Pfizer is also developing a GLP-1 weight-loss drug, an orally administered GLP-1 receptor agonist called danuglipron. Shares ...

Most of the world’s biggest news website saw strong growth in July in what was a bumper month for news. July saw an assassination attempt against Donald Trump, Joe Biden announcing he would not ...

Innovator drugs targeting glucagon-like peptide-1 receptor (GLP1R) witnessed a 595% increase in total licensing agreement deal value from 2019 to 2024 year-to-date (YTD), with more than $6.2bn forged ...

Pfizer Inc. (NYSE:PFE) recently confirmed that it will proceed with the development of danuglipron, an oral tablet that acts as a GLP-1 agonist and is used to treat weight reduction and diabetes.

It’s important to note that danuglipron has been studied in more than 1,400 patients globally, so we know a lot about the molecule. And now we are looking to develop the once-a-day pill.

WASHINGTON (AP) — Two years ago, Pfizer was the envy of the pharmaceutical world, with more than $100 billion in annual sales from its COVID-19 vaccine and antiviral Paxlovid. Today, CEO Albert Bourla ...